The need for minimally invasive approaches for diagnosis and monitoring of brain tumors for both primary and metastatic disease has prompted the emergence of liquid biopsy. Liquid biopsy offers technologic advancements for the measurement of circulating tumor biomarkers with continued refinements in standardization and improved signal detection. Datar Cancer Genetics Limited is committed to growing this area of molecular analysis.
Gliotrack™ from Datar Cancer Genetics Limited is one such promising technical advance that provides an alternative to tumor biopsy.
Gliotrack® is useful for cancer patients:
On treatment – to distinguish true disease progression from treatment associated changes like radiation necrosis and to monitor residual disease
With inadequate tissue sample for molecular stratification / prognostication
To select optimum therapy or to monitor therapy response
With suspected glioma on MRI
With glioma who are unfit for biopsy, e.g., diffuse intrinsic pontine glioma or associated comorbidities
To detect recurrence at the earliest
HOW IT WORKS?
Cell-free tumor DNA (cfDNA) is released by the dying tumor cells whereas mRNA and microRNA are actively secreted in the form of exosomes by the live tumor cells
These circulating biomarkers are involved in non-invasive assessment of tumor-derived molecular artifacts due to their high sensitivity and specificity. These biomarkers together represent the complete tumor activity
Gliotrack™ detects these tumor biomarkers, allowing precise non-invasive monitoring of cancer in real-time.
How it will help you?
- Molecular subclassification including indication of WHO grade
- Prognostic stratification of gliomas
- Assessment of disease burden
- Detection of therapy relevant biomarkers for predicting therapy efficacy
- Distinguishing true disease progression from pseudo progression e.g., treatment associated changes such as radiation necrosis
- Therapy response monitoring
- Detection of Immunotherapy efficacy associated marker – EGFR vIII
- Molecular classification of glioblastoma in distinct proneural, neural, classical and mesenchymal categories
What is the sample requirement?
10-20 mL of blood is obtained in special tubes from patients who present with a radiological mass lesion in the brain suggestive of glioma with or without a pathological diagnosis, those on current therapy for glioma, at post-therapy or at recurrence to guide therapeutic and prognostic decisions.
Where will the test be performed?
The analysis will be performed at the CAP accredited laboratory also accredited under ISO 15189:2012.
How is this test different from any other test in the market?
Currently used disease monitoring tools such as imaging are limited in detection of tumors that are a minimum 1-2 cm in dimensions. Invasive CNS biopsies are high risk, severely limiting the ability to intensively monitor the disease at close intervals. All the molecular and histological characterization is made on biopsy of tumors. Gliotrack® detects a much lower size of malignant lesion than any of the other methods available. Moreover, Gliotrack® is the only analysis, which can also give therapy guidance.
What is the public health significance?
Gliotrack® will have a significant impact on cancer detection. Being completely non-invasive, molecular profiling of deep-rooted cancer can be made easily. Real-time monitoring of the tumor can be done for the identification of new molecular alterations. This will have significant effect on health with remarkable cost savings by avoiding surgery for molecular profiling. Therapeutic decisions can be made on real-time tumor profile rather than at the time of surgery. Liquid biopsies can be rightly regarded as a cancer stethoscope, which helps in amplification of the tumor detection, non-invasively